Compare Pfizer Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROCE of 16.86%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 2.16 times
3
The company has declared Positive results for the last 3 consecutive quarters
4
With ROCE of 12.73%, it has a very attractive valuation with a 1.99 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 235,718 Million (Large Cap)
15.00
NA
409.58%
0.55
18.34%
2.66
Revenue and Profits:
Net Sales:
14,653 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,903 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.32%
0%
5.32%
6 Months
3.7%
0%
3.7%
1 Year
-3.66%
0%
-3.66%
2 Years
-9.89%
0%
-9.89%
3 Years
-46.67%
0%
-46.67%
4 Years
-53.56%
0%
-53.56%
5 Years
-30.46%
0%
-30.46%
Pfizer Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.35%
EBIT Growth (5y)
7.53%
EBIT to Interest (avg)
12.68
Debt to EBITDA (avg)
2.16
Net Debt to Equity (avg)
0.50
Sales to Capital Employed (avg)
0.43
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
119.94%
Pledged Shares
0
Institutional Holding
68.68%
ROCE (avg)
16.86%
ROE (avg)
21.23%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
2.48
EV to EBIT
15.64
EV to EBITDA
11.17
EV to Capital Employed
1.99
EV to Sales
4.31
PEG Ratio
0.13
Dividend Yield
428.12%
ROCE (Latest)
12.73%
ROE (Latest)
16.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 264 Schemes (28.78%)
Foreign Institutions
Held by 651 Foreign Institutions (15.41%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
14,653.00
13,715.00
6.84%
Operating Profit (PBDIT) excl Other Income
5,200.00
6,242.00
-16.69%
Interest
654.00
654.00
Exceptional Items
-186.00
-1,338.00
86.10%
Consolidate Net Profit
2,903.00
2,973.00
-2.35%
Operating Profit Margin (Excl OI)
244.00%
337.10%
-9.31%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 6.84% vs -22.79% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -2.35% vs 623.36% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
63,627.00
59,553.00
6.84%
Operating Profit (PBDIT) excl Other Income
23,496.00
11,582.00
102.87%
Interest
3,091.00
2,209.00
39.93%
Exceptional Items
-8,006.00
-7,474.00
-7.12%
Consolidate Net Profit
8,051.00
2,172.00
270.67%
Operating Profit Margin (Excl OI)
259.10%
88.90%
17.02%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.84% vs -40.64% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 270.67% vs -93.08% in Dec 2023
About Pfizer Inc. 
Pfizer Inc.
Pharmaceuticals & Biotechnology
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Company Coordinates 
Company Details
235 E 42ND ST , NEW YORK NY : 10017-5703
Registrar Details






